Compare Freeport-McMoRan Inc (FCX) vs Novavax Inc (NVAX) Price & Performance

FCX trades at $69.62, up 2.1% today, with a bullish technical signal from moving averages but overbought RSI near 86. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.68 above the $0.60 forecast. Revenue reached $25.92B in 2025, with net income margin improving to 8.5%. Recent news highlights progress at the Grasberg mine and strong copper prices supporting operations.

Outlook is positive with a consensus price target of $73.85, implying 6% upside, backed by 61% analyst buy ratings. Risks include reliance on commodity cycles and potential volatility from economic shifts. The company's solid cash flow and debt reduction trend provide stability, but investors should monitor copper market dynamics for sustained growth.

Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.

Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.